Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Pollen Allergenic Extract [EPC]
Carya Illinoinensis Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of IgE-mediated allergic diseases (Type I hypersensitivity) specifically related to pecan tree pollen sensitivity.
Name
Carya Illinoinensis Pollen
Raw Name
CARYA ILLINOINENSIS POLLEN
Category
Non-Standardized Pollen Allergenic Extract [EPC]
Drug Count
15
Variant Count
17
Last Verified
February 17, 2026
About Carya Illinoinensis Pollen
Carya Illinoinensis Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of IgE-mediated allergic diseases (Type I hypersensitivity) specifically related to pecan tree pollen sensitivity.
Detailed information about Carya Illinoinensis Pollen
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Carya Illinoinensis Pollen.
Carya Illinoinensis Pollen, commonly known as Pecan Pollen, is a biological substance utilized in the field of clinical allergology and immunology. It belongs to the pharmacological class known as Non-Standardized Pollen Allergenic Extracts [EPC]. These extracts are complex mixtures of proteins, glycoproteins, and polysaccharides derived from the male gametophytes (pollen) of the Carya illinoinensis tree, a member of the Juglandaceae family. In a clinical context, this extract is primarily used for two distinct purposes: the diagnosis of allergic sensitivity via skin testing and the long-term management of allergic rhinitis or asthma through Allergen Immunotherapy (AIT), often referred to as 'allergy shots.'
According to the FDA's regulatory framework for biological products, Carya Illinoinensis Pollen is classified as 'non-standardized.' Unlike 'standardized' extracts (such as those for short ragweed or certain dust mites), which have a proven potency measured in Bioequivalent Allergy Units (BAU) or Major Allergen Units (AU), non-standardized extracts like pecan pollen are typically labeled based on their Weight/Volume (w/v) ratio or Protein Nitrogen Units (PNU). This classification implies that while the extract contains the relevant allergenic proteins, the precise biological potency may vary between lots, requiring healthcare providers to exercise significant caution when transitioning patients between different batches of the medication.
The mechanism of action for Carya Illinoinensis Pollen depends entirely on the clinical application. For diagnostic purposes (skin prick testing), the extract is introduced into the epidermis. If the patient has pre-existing IgE (Immunoglobulin E) antibodies specific to pecan pollen allergens (such as the 11S globulin Car i 1), these antibodies, which are bound to the surface of mast cells and basophils, will cross-link upon contact with the extract. This cross-linking triggers the immediate degranulation of these cells, releasing inflammatory mediators like histamine, leukotrienes, and prostaglandins. This results in a localized 'wheal and flare' reaction within 15 to 20 minutes, confirming clinical sensitivity.
For therapeutic use (Allergen Immunotherapy), the mechanism is far more complex and involves a fundamental 're-training' of the immune system. When administered via subcutaneous injection in gradually increasing doses, Carya Illinoinensis Pollen induces a shift in the immune response from a Th2-dominated profile (which promotes allergy and IgE production) to a Th1-dominated profile. This process involves the induction of T-regulatory (Treg) cells, which produce inhibitory cytokines such as Interleukin-10 (IL-10) and Transforming Growth Factor-beta (TGF-β). Over time, this leads to the production of 'blocking antibodies' known as IgG4. These IgG4 antibodies compete with IgE for allergen binding, effectively preventing the mast cell degranulation that causes allergy symptoms. Furthermore, long-term immunotherapy can lead to a decrease in the recruitment of eosinophils and mast cells to the respiratory mucosa, providing long-lasting relief even after the treatment is discontinued.
Traditional pharmacokinetic parameters (Absorption, Distribution, Metabolism, and Elimination) do not apply to allergenic extracts in the same way they do to small-molecule drugs. Because these are complex biological mixtures administered locally or subcutaneously to elicit an immunological response, their 'movement' through the body is not the primary driver of efficacy.
Carya Illinoinensis Pollen is FDA-approved for the following indications:
Carya Illinoinensis Pollen is available in the following formats:
> Important: Only your healthcare provider can determine if Carya Illinoinensis Pollen is right for your specific condition. Immunotherapy should only be administered in a clinical setting equipped to treat anaphylaxis.
Dosage for Carya Illinoinensis Pollen is highly individualized and must be determined by an allergist based on the patient's level of sensitivity. There is no 'standard' dose for all patients.
Carya Illinoinensis Pollen is generally considered safe for use in children, though it is rarely initiated in children under the age of 5 due to the difficulty of communicating systemic symptoms and the potential for trauma associated with frequent injections. Dosing protocols for children are identical to adult protocols but may be adjusted more conservatively if the child is highly sensitive.
No specific dose adjustments are required for patients with renal impairment, as the proteins are not cleared via traditional renal filtration mechanisms. However, the patient's overall health must be stable.
No dose adjustments are necessary for hepatic impairment. The liver does not play a role in the processing of allergenic extracts.
Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The risk of using epinephrine (the treatment for a reaction) in an elderly patient with heart disease must be weighed against the benefits of the immunotherapy.
This medication is NEVER for self-administration. It must be administered subcutaneously (under the skin) by a trained healthcare professional.
If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on how much time has passed. If a maintenance dose is missed by more than 2-3 weeks, the allergist will typically reduce the dose to ensure safety before building back up to the maintenance level.
An 'overdose' in the context of Carya Illinoinensis Pollen refers to an injection of a dose higher than the patient's current tolerance level. This can lead to a systemic allergic reaction or anaphylaxis.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
Local reactions at the site of injection are the most frequent side effect of Carya Illinoinensis Pollen immunotherapy. These are generally considered a normal part of the body's response to the extract.
These reactions are slightly more concerning and may indicate that the dose is being increased too rapidly.
> Warning: Stop taking Carya Illinoinensis Pollen and call your doctor immediately if you experience any of these.
There are no known long-term 'toxic' effects of Carya Illinoinensis Pollen. Unlike many medications, the long-term effect of this treatment is intended to be beneficial—a permanent or semi-permanent reduction in allergic sensitivity. However, some patients may develop a persistent sensitivity at the injection site (granuloma), though this is extremely rare with modern extracts.
While Carya Illinoinensis Pollen may not have a specific 'Black Box' in the same way as a new chemical entity, all allergenic extracts carry a standardized FDA-mandated warning regarding the risk of severe systemic reactions.
Summary of Warning: This product can cause severe life-threatening systemic reactions, including anaphylaxis. It should only be administered by physicians who are exceptionally experienced in the treatment of allergic diseases and who are prepared to manage a life-threatening emergency. Patients with unstable asthma are at a higher risk for fatal reactions. Patients taking beta-blockers may be resistant to the effects of epinephrine used to treat a reaction.
Report any unusual symptoms to your healthcare provider.
Carya Illinoinensis Pollen is a potent biological product that must be handled with extreme care. The primary safety concern is the risk of an IgE-mediated systemic allergic reaction. Patients must be informed that even if they have tolerated previous injections well, every injection carries a small but real risk of a severe reaction. Environmental factors, such as high pollen counts, recent exercise, or a viral infection, can lower a patient's 'allergic threshold' and make a reaction more likely on a given day.
No specific 'Black Box' warning is uniquely assigned to Carya Illinoinensis Pollen, but it falls under the general class warning for all allergenic extracts. This warning emphasizes that the product should only be used by clinicians equipped to manage anaphylaxis and that patients must be observed for 30 minutes post-injection. It also highlights that the risk of a fatal reaction is significantly increased in patients with poorly controlled asthma.
Carya Illinoinensis Pollen does not typically cause drowsiness or impairment. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive until cleared by a medical professional.
There is no direct interaction between Carya Illinoinensis Pollen and alcohol. However, alcohol consumption can cause vasodilation (widening of blood vessels), which could theoretically accelerate the absorption of the allergen or worsen the symptoms of an allergic reaction. It is generally advised to avoid heavy alcohol use on the day of an injection.
Unlike many medications, Carya Illinoinensis Pollen does not need to be 'tapered' to avoid withdrawal. It can be stopped at any time. However, stopping immunotherapy before the 3-to-5-year mark usually results in the return of allergy symptoms over time.
> Important: Discuss all your medical conditions with your healthcare provider before starting Carya Illinoinensis Pollen.
There are no drugs that are strictly 'contraindicated' in the sense that they cause a chemical reaction with the pollen extract. However, certain drugs make the management of a side effect nearly impossible:
There are no well-documented interactions between Carya Illinoinensis Pollen and herbal supplements. However, supplements that have 'immune-boosting' claims (like Echinacea) should be discussed with an allergist, as the goal of immunotherapy is immune modulation, not general stimulation.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Carya Illinoinensis Pollen must NEVER be used in the following circumstances:
These conditions require a careful risk-benefit analysis by the allergist:
Carya Illinoinensis is closely related to other members of the Juglandaceae family. Patients who are highly sensitive to Pecan Pollen may also react to:
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Carya Illinoinensis Pollen.
Carya Illinoinensis Pollen extracts are not known to pass into breast milk in any form that would affect a nursing infant. The large proteins are broken down locally at the injection site. Breastfeeding is not a contraindication for immunotherapy.
Patients over age 65 are at a higher risk for complications from immunotherapy due to the higher prevalence of cardiovascular disease. The ability of an older patient to tolerate a systemic reaction and the subsequent 'adrenaline rush' of epinephrine treatment must be carefully evaluated.
No specific adjustments are needed. The proteins in the extract are not cleared by the kidneys in their active form. However, patients with end-stage renal disease should be medically stable before starting any biological therapy.
No adjustments are required. The liver is not involved in the immunological processing of allergenic extracts.
> Important: Special populations require individualized medical assessment.
Carya Illinoinensis Pollen acts as an immunomodulator. At the molecular level, the extract provides the specific antigens (proteins) necessary to engage the patient's immune system. Upon subcutaneous injection, these antigens are taken up by peripheral dendritic cells (antigen-presenting cells). These cells travel to the local lymph nodes and present the pecan allergens to 'naive' T-cells. In an allergic individual, this presentation normally results in Th2 cell activation. However, the repeated, high-dose exposure provided by immunotherapy forces the immune system to adapt. This leads to the 'immune deviation' toward a Th1 response and the generation of CD4+ CD25+ Foxp3+ regulatory T-cells (Tregs). These Tregs secrete IL-10, which suppresses IgE production and increases the production of IgG4, a non-inflammatory antibody that 'blocks' the allergen before it can reach the IgE on mast cells.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Administered for local immune interaction) |
| Protein Binding | N/A (Interacts with antibodies and cell receptors) |
| Half-life | Hours (for the proteins); Years (for the immune memory) |
| Tmax | 15-30 minutes (for local IgE interaction) |
| Metabolism | Proteolysis by tissue proteases and lysosomal enzymes |
| Excretion | Renal (as small peptide fragments/amino acids) |
Carya Illinoinensis Pollen is a member of the 'Allergenic Extracts' class. It is specifically a 'Non-Standardized Pollen Extract.' Related medications include extracts for Oak, Maple, and Hickory pollen.
Common questions about Carya Illinoinensis Pollen
Carya Illinoinensis Pollen extract is primarily used for the diagnosis and treatment of allergies to pecan tree pollen. In a diagnostic setting, it is used during skin prick tests to confirm if a patient is sensitive to this specific allergen. For treatment, it is used in allergen immunotherapy, commonly known as allergy shots, to help the body build a tolerance over time. This process involves regular injections of small, increasing amounts of the pollen extract. The goal is to reduce symptoms like sneezing, itchy eyes, and asthma flares during pecan pollination season.
The most frequent side effects are localized reactions at the site of the injection, such as redness, swelling, and itching. These reactions are usually mild and feel similar to a mosquito bite, typically resolving within 24 hours. Some patients may also experience large local reactions where the swelling exceeds two inches in diameter. While less common, some people feel tired or experience a temporary increase in their hay fever symptoms after a shot. Serious systemic reactions like hives or difficulty breathing are rare but require immediate medical attention.
While there is no direct chemical interaction between alcohol and Carya Illinoinensis Pollen extract, healthcare providers generally recommend avoiding alcohol on the day of your injection. Alcohol can cause your blood vessels to dilate, which might speed up the absorption of the allergen into your bloodstream, potentially increasing the risk of a reaction. Furthermore, alcohol can mask the early symptoms of an allergic reaction or make them more difficult to manage. It is best to wait until the day after your injection to consume alcohol. Always follow the specific advice provided by your allergist.
Carya Illinoinensis Pollen immunotherapy is generally not started during pregnancy because of the risk that a systemic reaction could harm the developing fetus. However, if a woman is already on a stable maintenance dose when she becomes pregnant, most allergists will continue the treatment. The dose is usually kept the same and not increased until after delivery to minimize the risk of anaphylaxis. Continuing maintenance therapy is often considered safer than stopping, as it prevents a surge in allergy symptoms. You must inform your doctor immediately if you become pregnant while receiving these injections.
Allergen immunotherapy with Carya Illinoinensis Pollen is a long-term commitment and does not provide immediate relief. Most patients do not notice a significant reduction in their allergy symptoms during the 'build-up' phase, which usually lasts three to six months. Improvement typically becomes noticeable during the first year of reaching the maintenance dose. For the best and most lasting results, the treatment is usually continued for three to five years. This duration allows the immune system to fundamentally change its response to the pollen.
Yes, you can stop taking Carya Illinoinensis Pollen injections at any time without experiencing physical withdrawal symptoms. Unlike some medications, these extracts do not cause chemical dependency. However, if you stop the treatment before completing the recommended three-to-five-year course, your allergy symptoms are likely to return over time. The 'tolerance' built up by the immune system may not be permanent if the treatment is cut short. If you are considering stopping your shots, you should discuss your reasons with your allergist first.
If you miss a dose, you should contact your allergist's office to reschedule as soon as possible. The protocol for a missed dose depends on how long it has been since your last injection and whether you are in the build-up or maintenance phase. If only a few days have passed, you may be able to continue with your scheduled dose. However, if several weeks have passed, your doctor will likely need to reduce your dose for safety reasons before gradually increasing it again. Never try to 'double up' on doses to make up for a missed one.
There is no clinical evidence to suggest that Carya Illinoinensis Pollen extracts cause weight gain. The extract consists of proteins and naturally occurring substances that are administered in very small quantities subcutaneously. It does not contain hormones, steroids, or calories that would affect your metabolic rate or appetite. If you experience weight changes while on immunotherapy, they are likely due to other factors such as lifestyle changes or other medications you may be taking. Always discuss unexplained weight changes with your primary care physician.
Carya Illinoinensis Pollen can be taken alongside most common medications, but there are important exceptions. You must tell your doctor if you are taking beta-blockers, which are often prescribed for heart conditions or high blood pressure, as they can make it dangerous to treat an allergic reaction. ACE inhibitors and MAO inhibitors also require special consideration. Most allergy medications, like antihistamines and nasal steroids, are perfectly fine to use and may even be recommended to manage symptoms during the build-up phase. Always provide your allergist with a complete list of your current medications.
Allergenic extracts like Carya Illinoinensis Pollen are biological products rather than simple drugs, so the term 'generic' does not apply in the traditional sense. However, several different manufacturers produce pecan pollen extracts. While they all contain the same basic allergens from the *Carya illinoinensis* tree, they are 'non-standardized,' meaning the exact potency can vary between manufacturers. Because of this, allergists generally do not switch between different brands of extract once a patient has started treatment unless they carefully adjust the dose to ensure safety.